Incyte scraps BET inhibitor against backdrop of safety concerns for the drug class
Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class. The biopharma, which markets Novartis-partnered blockbuster myelofibrosis…